Cyteir Therapeutics, Inc. (NASDAQ:CYT) announced its intent to delist its common stock from the Nasdaq Global Select Market, with trading suspension effective before the market opens on March 18, 2024. This move precedes the company's filing of a certificate of dissolution on March 20, 2024, and the closure of its stock transfer books. The official delisting is expected to be effective on March 28, 2024. This decision is part of Cyteir's Plan of Complete Liquidation and Dissolution, approved by its board and stockholders, due to the costs and burdens of being a publicly traded company amidst its planned dissolution.